NIH Funding Opportunities

Pediatric Immunotherapy Discovery and Development Network (PI-DDN)(U54 - Clinical Trial Not Allowed)

Funding Opportunity RFA-CA-19-003 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to establish centers of collaborating investigators with the goal of identifying and advancing research opportunities for translating immunotherapy concepts for children and adolescents with cancer toward clinical applications. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation (B) that calls for the establishment of a pediatric immunotherapy translational science network. The network was envisioned by the BRP as focusing on identifying new targets for immunotherapies, developing new pediatric immunotherapy treatment approaches (e.g., cancer vaccines, cellular therapy, combinations of immunotherapy agents, and others), and defining the biological mechanisms by which pediatric tumors evade the immune system. The Pediatric Immunotherapy Discovery and Development Network (PI-DDN) Centers will address and implement these BRP recommendations.

Pediatric Immunotherapy Discovery and Development Network (PI-DDN)(U01 - No Clinical Trial Allowed)

Funding Opportunity RFA-CA-19-004 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The overall goal of this FOA and the companion FOA, RFA-CA-19-012, is to establish a network of collaborating investigators to identify and advance research opportunities for translating immunotherapy concepts for children and adolescents with cancer toward clinical applications. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation (B) that calls for the establishment of a pediatric immunotherapy translation science network. The network was envisioned by the BRP as focusing on identifying new targets for immunotherapies, developing new pediatric immunotherapy treatment approaches (e.g., cancer vaccines, cellular therapy, combinations of immunotherapy agents, and others), and defining the biological mechanisms by which pediatric tumors evade the immune system. This FOA solicits U01 applications for discrete research projects that address relevant research opportunities (e.g., mechanisms of immune evasion, model development, validation of a single target, etc.), whereas the companion FOA, RFA-CA-19-003, solicits multi-component U54 Center applications. Successful applicants from both FOAs will become members of the Pediatric Immunotherapy Discovery and Development Network (PI-DDN), which will address and implement the BRP recommendations.

Chronic, Non-Communicable Diseases and Disorders Across the Lifespan: Fogarty International Research Training Award (NCD-LIFESPAN) (D43)(Clinical Trial Optional)

Funding Opportunity PAR-18-901 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages applications for the Chronic, Non-Communicable Diseases and Disorders Across the Lifespan: Fogarty International Research Training Award (NCD-LIFESPAN) D43 program for institutional research training programs in low-and middle-income countries (LMICs, as defined by the World Bank classification system). Applications may be for collaborations between institutions in the U.S and an eligible LMIC or may involve just LMIC institutions if there is a previous track record of externally funded research and/or research training programs by the lead LMIC institution. The proposed institutional research training program is expected to sustainably strengthen the NCD research capacity of the LMIC institutions, and to train in-country experts to develop and conduct research on NCDs across the lifespan, with the long-range goal of developing and implementing evidence-based interventions relevant to their countries. The main focus of research training covered in the application must be relevant to the interests of at least one of the participating NIH ICs as stated by each in this FOA. Other NCD topics may be included as secondary and complementary focus areas.

Pre-Application: Research Innovation for Scientific Knowledge (RISK) for Skin and Rheumatic Diseases (X02 Clinical Trial Not Allowed)

Funding Opportunity PAR-18-899 from the NIH Guide for Grants and Contracts. The NIAMS Research Innovation for Scientific Knowledge (RISK) for Skin and Rheumatic Diseases initiative focuses on innovative research within the NIAMS mission by encouraging applicants to pursue unusual observations, test imaginative hypotheses, investigate creative concepts, and build ground-breaking paradigms, all of which deviate significantly from the current prevailing theories or practice. This FOA is particularly designed to encourage the submission of projects that are considered too risky, premature, controversial, or unconventional for other NIH mechanisms. This FOA intends to support disease-focused translational studies. We invite research studies aimed at understanding the mechanisms of diseases or conditions relevant to the NIAMS mission, as well as studies aimed at developing or testing diagnostics, therapeutic agents, or preventive interventions up to, but not including, first in human studies. The RISK X02 and R61/R33 FOAs are not intended to support clinical trials. The RISK program will support the two main scientific areas of NIAMS mission, 1) musculoskeletal diseases and 2) the skin and rheumatic diseases. This X02 pre-application and the companion R61/R33 (RFA- AR-19-012) encourage applications related to skin and rheumatic diseases. The X02 pre-application is the highly recommended (not required) first step in the application process for the companion R61/R33 (RFA-AR-19-012). Potential applicants should read both FOAs. Investigators whose X02 pre-applications are evaluated to be highly innovative and most relevant to the RISK program will be notified of the opportunity to submit an R61/R33 application under RFA-AR-19-012.

Novel and Innovative Tools to Facilitate Identification, Tracking, Manipulation, and Analysis of Glycans and their Functions (U01 Clinical Trial Not Allowed)

Funding Opportunity RFA-RM-18-036 from the NIH Guide for Grants and Contracts. The Common Fund Program - Accelerating Translation of Glycoscience: Integration and Accessibility - aims to develop accessible and affordable new tools and technologies for studying carbohydrates that will allow biomedical researchers to significantly advance our understanding of the roles of these complex molecules in health and disease. This program will enable investigators who might not otherwise conduct research in the glycosciences, to undertake the study of carbohydrate structure and function. This FOA solicits development of new, more easily accessible tools, reagents, and technologies to facilitate identification, tracking, manipulation, and analysis of glycans with their biological binding partners and determine their functions. This initiative may build on efforts that interface with existing technologies and procedures to make them easier to access and use. As applicable, efforts must consider: factors for scale-up; efforts to make instrumentation broadly accessible and cost-effective for the end-user; and compatibility of data generated with integration into existing databases. While this FOA seeks development of new or more robust tools and technologies, the related RFA RM-18-037 is a solicitation for adaptation of existing technologies for simplification and ease of accessibility to the greater biomedical research community.

Innovative Adaptations to Simplify Existing Technologies for Manipulation and Analysis of Glycans (U01 Clinical Trial Not Allowed)

Funding Opportunity RFA-RM-18-037 from the NIH Guide for Grants and Contracts. The Common Fund Program - Accelerating Translation of Glycoscience: Integration and Accessibility - aims to develop accessible and affordable new tools and technologies for studying carbohydrates that will allow biomedical researchers to significantly advance our understanding of the roles of these complex molecules in health and disease. This program will enable investigators who might not otherwise conduct research in the glycosciences, to undertake the study of carbohydrate structure and function. This FOA solicits development of innovative adaptations of existing technologies to enable their use for readily identifying, manipulating, or analyzing glycans and their biological binding partners. This may encompass the adaptation of commonly used laboratory-based or computational tools to enable their facile application to glycoscience for the first time, as well as the adaptation of tools presently used by specialists in glycoscience to make them significantly more straightforward and accessible for non-specialists. It is possible that a project might simplify a current specialized approach by migrating it to a more commonly used platform, developing automation for data acquisition and interpretation, or redesigning the present tool to make it easier to use. This announcement differs from the related RFA RM-18-036 which solicits new or more effective tools or technologies, thus representing an expansion of existing technologies.

Human Islet Research Network - Consortium on Human Islet Biomimetics (HIRN-CHIB) (UG3/UH3 Clinical Trial Not Allowed)

Funding Opportunity RFA-DK-18-011 from the NIH Guide for Grants and Contracts. This FOA invites new applications to participate in the Human Islet Research Network-Consortium on Human Islet Biomimetics (HIRN-CHIB). NIDDK will support the development of a microphysiological system (MPS) that allows the study of interactions between primary human islets or assembled islet spheroids (organoids made up of human beta/alpha/delta/other cells) and immune cells within a 3D microenvironment to mimic aspects of the autoimmune process and its regulation. The ultimate goal will be to create an in vitro human disease model(s) that could recapitulate some aspects of the complex pathophysiology of Type 1 diabetes (T1D), by using T1D patient-derived islets (created using induced pluripotent stem cells (iPSCs) combined with autologous immune components. CHIB is already part of HIRN, whose overall mission is to support innovative and collaborative translational research to understand how human beta cells are lost in T1D, and to find innovative strategies to protect and replace functional beta cell mass in humans.

Páginas